Throughout the manuscript the term "well-anticoagulated" is used. This should be either be backed up with information on adherence and INR values, or completely removed and noted as a limitation of the study. This cannot solely be based on incidence rates of bleeding and stroke in the population.
How was cardiac or non-cardiac mortality ascertained? Were postmortem performed in all cases?
It would be relevant to know for how long time the included patients have had their AF diagnosis, and what clinical actions had been performed to manage the disease (besides OAC treatment) -including rhythm and rate control within (e.g.) last year, ablation, etc.. In general, the characterization of the patient population is difficult to fully understand, since the included patients had prevalent AF within a window of inclusion. Hence, the data cannot fully describe the course of the disease, but rather provides a snapshot of current practice in this population.
Loss to follow-up could occur in this cohort; this requires attention. Please provide information on the proportion lost to follow-up, and also how these patients potentially differed from the studied cohort. Are the results generalizable to a broad(er) community-dwelling population?
Minor comments: Page 7, line 113: "Follow-up lasted…" the meaning is unclear. Perhaps the authors mean "Patients were followed up for at least two years"? Page 8, line 146: This does not guarantee that data was not missing. Rather, the authors constructed their variable based on presence of a diagnose code, and in absence they assumed that the disease was not present. This is an important distinction and relates to validity of the coding in the files.
VERSION 1 -AUTHOR RESPONSE

Reviewer: 1
In the Introduction the authors cite articles on the situation in the World and in Europe, but as there are many articles on this topic, they could preferably choose others as well, also comparing the situation in the Netherlands with similar European countries.
We agree with the reviewer that many articles on the epidemiology of atrial fibrillation exist, and provided additional references specific to the Dutch and European population:
Atrial fibrillation (AF) is the most common cardiac arrhythmia with a prevalence of 1-2% 
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The authors have presented data on several diagnoses. How valid are these? They show data from primary care as well as from hospitals; are earlier diagnoses from hospitals known and registered in electronic patient records in primary care?
These are valid points. The basis of our data collections were primary care practices. In the Netherlands, general practitioners (GPs) regularly receive letters from hospital specialists, including all hospital diagnoses and also including all diagnoses made in secondary care without involvement from the GP. This information is then subsequently added to the medical file from the GP. As such, we believe this medical information can be considered (fairly) complete. In primary care, we then manually screened the complete medical files to ascertain the presence or absence of all variables (i.e. 'diagnoses') of the CHA2DS2-VASc model. As we had access to all specialists' letters from hospitals, we could (as said) include diagnoses both established and recorded in general practice, as well as these established in hospitals. This is now more clearly stated in the 'Methods' section of our manuscript:
Subsequently, for every identified patient, the electronic patient file in general practice was manually screened by the researchers for correctness of AF diagnosis, i.e. whether it was indeed confirmed by electrocardiography. Furthermore, to avoid misclassification all available information including diagnostic test results, out-of-hours office reports and specialists' letters (that are regularly received by GPs in the Netherlands) was used to assess the correctness of the important stroke risk predictors (i.e. diagnoses included in the CHA2DS2-VASc stroke prediction model either established in general practice or in hospitals).
Data are presented for reasons for hospitalization; however, reality could be more complex with a combination of diseases as the reason for a hospitalization. How were the reasons for hospitalization validated?
We strongly agree with the reviewer that multiple reasons may have led to hospitalisation, especially in the case of the frail and multimorbid AF patients included in our study. As described above, we used all available information in the electronic file including hospital discharge letters to decide on the primary cause for hospital admission. This is now clarified in our manuscript: We agree that potential differences between males and females would be of interest. Prompted by this comment, we stratified our analyses by sex and found that this did not change our inferences as results for both for hospitalization and mortality were similar. For completeness, see the results of the multivariable analyses the table below.
Risk factors for hospitalisation:
All A remark is now added to the 'Results' section of our manuscript:
While previous stroke was also predictive In the Cox regression HR results for age is probably by one year, and for CHA2DS2-VASc scores but one point, but this needs to be clarified in the Tables.
Indeed, the reviewer is right and thank him for pointing this out, the Tables are now clarified.
In the section of strengths and limitations the authors mention that the sample is large and that this is a strength. They should rather say "fairly large", and the statistical power is somewhat low for some outcomes, as shown in Table 3 . The prospective approach is surely a strength, as well as the approach not only to show CVD but also non-CVD events.
Indeed, compared to the contemporary large population-based observational studies, i.e. those using data obtained from routine health care, our study is 'fairly large'. We changed this in our manuscript, also stressing that for some outcomes statistical power is somewhat low. We greatly thank the reviewer for recognising additional strengths of our study, including the prospective nature and inclusion of non-cardiac causes for hospitalisation and mortality. We added these to the relevant section of our manuscript.
In Supplementary Table 1 the authors present most frequently prescribed drugs; is it necessary to show all prescriptions, including drugs for topical use?
We thank the reviewer for carefully examining the full submission including supplementary Table 1, and raising this interesting issue. We agree that one might question whether drugs for topical use are much informative when studying multimorbidity in atrial fibrillation. However, while the use of topical drugs by itself may not pose that great a burden to patients with AF, they do illustrate that yet another organ system (in this particular case the skin) may be compromised and in need of medical attention.
Although we completely agree with the reviewer that adding topical drugs into the list is 'a matter of taste', we deliberately choose all drugs to be shown in Supplementary Unfortunately, given the pragmatic nature of our study design, no post-mortem investigations were performed. As stated in the 'Methods' section, we studied the electronic patient file to decide on the most likely cause of mortality. As the files contained all available information both from general practice as well as from hospital care, misclassification on these outcomes at least as ascertained in clinical practice was not likely. Of course, we know that rigorous post-mortem examinations sometimes reveal different diseases as the cause of death than originally suspected. We would also like to refer to our answers to the questions from reviewer 1 on the validity of the obtained information used in our analyses. Indeed, all patients in our study were prevalent cases of AF. As such, we have no data on the exact duration of AF, although in general this is always difficult to precisely record given that many AF cases are 'screen detected' during e.g. blood pressure controls or picked-up in older patients with usually longstanding and slow progressive symptoms of fatigue, shortness of breath on exertion or a general feeling of (chest) discomfort. Nevertheless, we agree with the reviewer that some insight in the management of the disease may help to understand the patient characteristics and case-mix included in our study. As an example, the median age of 78 years and the multitude of hospitalisations occurring in the patients in our study, very well illustrate that these prevalent AF cases are predominantly frail and at risk of morbidity and mortality as is often the case in general practice.
It
To help characterise the patients though, as prompted by this comment, we now present available data on rhythm control medication at baseline, and attempts at rhythm control by means of cardioversions and arrhythmia surgery during follow-up in the 'Results' section of our manuscript: Loss to follow-up could occur in this cohort; this requires attention. Please provide information on the proportion lost to follow-up, and also how these patients potentially differed from the studied cohort. Are the results generalizable to a broad(er) communitydwelling population?
We thank the reviewer for pointing out this issue. Although constituting only a small proportion, some patients left the cohort during follow-up after which any data on the endpoints could not be collected anymore. We now present the proportion of patients that was lost to follow-up, how they compare to patients that completed follow-up and, in our opinion of most interest, the reason for leaving the cohort: 
Minor comments:
Page 7, line 113: "Follow-up lasted…" the meaning is unclear. Perhaps the authors mean "Patients were followed up for at least two years"?
We thank the reviewer for this suggestion and rephrased this sentence accordingly. Indeed, for the collection of data in our study we entirely relied on information recorded during routine healthcare. However, as mentioned in the 'Methods' section of our manuscript, for this reason the most important diagnoses (i.e. known stroke risk predictors) as well as for the outcomes under study (stroke, hospitalisation and mortality) we carefully scrutinised using the complete electronic patient file, which notably also included all consultations with the GP for new-onset of symptoms. As mentioned above, this is now more clearly described in our manuscript.
Furthermore, we previously showed that even substantial misclassification in routine healthcare data did only marginally affect multivariate analyses in prognostic research such as our study.
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This leads us to believe that, even though misclassification could indeed not completely avoided, our inferences are unbiased.
